60P - Evaluating the potential of 99mTc-etarfolatide to select NSCLC patients likely to benefit from vintafolide treatment

Date 28 March 2014
Event ELCC 2014
Session Lunch and poster display session
Topics Anti-Cancer Agents & Biologic Therapy
Non-Small-Cell Lung Cancer, Metastatic
Imaging, Diagnosis and Staging
Presenter Wael Harb
Citation Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131
Authors W. Harb1, P. Bonomi2, J. Symanowski3, B. Nguyen4, M. Edelman5
  • 1Inc., Horizon Oncology Research, 47905 - Lafayette/US
  • 2Hematology/oncology, Rush University Medical Center, Chicago/US
  • 3Cancer Biostatistics, Levine Cancer Institute, Carolinas Healthcare System, Charlotte/US
  • 4Medical Affairs, Endocyte Inc., West Lafayette/US
  • 5Cancer Center, University of New Mexico Cancer Center, Albuquerque/US


Folate receptor (FR) is expressed in non-small cell lung cancer (NSCLC) tumors, making it potentially useful as a biomarker and a therapeutic target. Vintafolide is a potent drug conjugate of folic acid and the vinca alkaloid desacetylvinblastine hydrazide. 99mTc-etarfolatide, a technetium bound folate molecule, allows for full body, real-time, SPECT imaging of FR. These two companion agents are being co-developed. This study aimed to evaluate the ability of 99mTc-etarfolatide imaging to identify FR expression in NSCLC patients’ tumors and to correlate this with response to vintafolide.